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ABSTRACT
We retrospectively studied 49 patients in a single institute to evaluate the long-term outcome of total lymphoid
irradiation (TLI) conditioning for allogeneic stem cell transplantation (allo-SCT) to treat aplastic anemia (AA).
Most of the patients had received transfusions and had undergone previous treatment, with 33 receiving related
transplants and 16 receiving unrelated transplants. Conditioning consisted of cyclophosphamide (Cy; 200mg/kg)
plus TLI (750 cGy) for related transplantation and Cy plus total body irradiation (TBI; 500 cGy) and TLI (500
cGy) for unrelated transplantation. Antithymocyte globulin (ATG) was added for 6 of the unrelated transplanta-
tions. Graft-versus-host-disease (GVHD) prophylaxis consisted mainly of cyclosporine (CSA) andmethotrexate
(MTX).Graft failure developed in 2 patients (4.1%).With amedian follow-up of 7 years, overall survival (OS)was
81% and was not statistically significantly different between the patients receiving related transplants and those
receiving unrelated transplants. In multivariate analyses, a history of previous treatment with ATG was the sole
factor associated with a worse survival rate, and the interval from diagnosis to treatment was not prognostic. The
incidence of acute (grade II to IV) GVHD (aGVHD) was 23%, and that of chronic GVHD (cGVHD) was 29%.
Female-to-male transplantation was the sole factor associated with chronic GVHD. B cell lymphoproliferative
disorder developed only after the ATG-containing conditioning. No other secondary malignancies developed
after long-term follow-up.Our findings suggest thatTLI conditioning is feasible and effective for patientswith AA.
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Allogeneic stem cell transplantation (allo-SCT) is
a curative treatment strategy for patients with aplastic
anemia (AA). A randomized prospective study showed
that allo-SCT is the first choice of treatment for pa-
tients with severe AA who receive transplants from
HLA-matched related donors [1]. Long-term compli-
cations, such as chronic graft-versus-host disease
(-GVHD), secondary malignancies, and late infections,
have been reported after allo-SCT [2,3]. Although the
response rate and survival after immunosuppressivetherapy are improving, problems remain, including
incomplete response, clonal evolution, relapse, and
cyclosporine (CsA) dependence [4].
A major problem with transplantation for AA has
been graft failure [5]. The use of irradiation as part of
the conditioning regimen has successfully reduced the
failure rate, [6], although it may increase the risk of
acute GVHD (aGVHD), secondary malignancies,
and infertility [7,8]. Although encouraging results
have been reported by the Seattle group using a novel
conditioning regimen with cyclophosphamide (Cy)43
44 Y. Inamoto et al.plus antithymocyte globulin (ATG) [9], other studies
have reported that using ATG as part of the condition-
ing regimen increased graft failure, mixed chimerism,
andBcell lymphoproliferativedisorder (BLPD) [10-12].
Excellent results of a conditioning regimenwithCy
plus total lymphoid irradiation (TLI) were reported in
1980 [13], and we began to use this regimen for related
transplantation [14]. Considering the higher incidence
of graft failure, the regimen was intensified with low-
dose total body irradiation (TBI) for unrelated trans-
plantation. To clarify the long-term outcome of TLI
conditioning for AA, we conducted a retrospective
study of 49 consecutive patients in a single institute.
TLI conditioning proved to be a feasible and effective
modality, with no secondary malignancies other than
BLPD observed after long-term follow-up.
PATIENTS AND METHODS
Patients
Between 1984 and 2006, we evaluated a total of 49
consecutive allo-SCTs done for AA at the Japanese
Red Cross Nagoya First Hospital. Three patients
who had been conditioned with Cy alone before
1983 were not included. All patients provided written
informed consent. The stem cell source was bone mar-
row in all patients.
Conditioning Regimen, GVHD Prophylaxis, and
Supportive Therapy
The Cy1TLI regimen for related transplantation
consisted of Cy 50 mg/kg once daily intravenously
(i.v.) from days 26 to 23 (total dose, 200 mg/kg)
and TLI 750 cGy on day 21. The Cy 1 TBI 1 TLI
regimen for unrelated transplantation consisted of
Cy 50 mg/kg once daily i.v. from days26 to23 (total
dose, 200 mg/kg), TBI 500 cGy divided into 2 frac-
tions (6.5 cGy/min) on day 22 and TLI 500 cGy on
day 21. (Initially, TLI was given in a single fraction
at a dose rate of 26 cGy/min; however, since 1996, after
radiation hepatitis developed in 1 patient [15], it has
been divided into 2 fractions at the same dose rate.)
ATG was added at a dose of 2.5 mg/kg once daily
i.v. from days25 to22 (total dose, 10mg/kg) for 6 pa-
tients who received unrelated transplants. However,
the use of ATG has been proscribed since 2000 after
BLPD developed in 3 consecutive patients. Donor-
derived bone marrow was infused on day 0 without
any manipulations. GVHD prophylaxis comprised CsA
alone, CsA and methotrexate (MTX), or tacrolimus
and MTX. Patients were treated in laminar airflow
rooms. Antimicrobial prophylaxis included levofloxa-
cin (since 1995), fluconazole (200 mg/day, since
1995), trimethroprim/sulfametoxasole, and acyclovir.
Since 1990, monitoring for cytomegalovirus (CMV)
antigenemia has been performed every week after
engraftment up to day 1100, with ganciclovir therapyinstituted for positive assays. Since 1990, 42 patients
have received granulocyte colony-stimulating factor
(G-CSF) i.v. daily beginning on day 17 until an abso-
lute neutrophil count (ANC) of . 1.5  109/L for 3
consecutive days was achieved. One patient received
granulocyte-macrophage colony-stimulating factor
(GM-CSF) in 1989.
Statistical Analysis
The aim of the present study was to evaluate the
long-term efficacy, complications, and mortality of
transplantation for AA with TLI conditioning. The
engraftment, overall survival (OS), relapse rate, inci-
dence of aGVHD and cGVHD, factors affecting OS
and chronic GVHD, as well as secondary malignancies
were evaluated. Engraftment was defined as ANC .
0.5  109/L for 3 consecutive days. OS was calculated
using the Kaplan-Meier method, and P values were
calculated using the log-rank test. aGVHDwas graded
based on previously established criteria [16]. cGVHD
was evaluated in patients surviving beyond day 1100
and was classified as limited or extensive according
to the Seattle criteria [17]. Cumulative incidences
of aGVHD and cGVHD were estimated by Gray’s
method, with deaths not related to GVHD treated as
competing risks. Univariate and multivariate analyses
were performed using the Cox proportional hazard re-
gression model. A 2-sided P value of\ .05 was consid-
ered significant. Data analyses were completed as of
January 2007.
RESULTS
Patient Characteristics
Patient characteristics are summarized in Table 1.
The causes of AA were idiopathic (n5 47) and hepati-
tis (n 5 2). The severity of disease at transplantation
was moderate (n 5 8) and severe (n 5 41), according
to Camitta’s criteria [1]. All patients in the moderate
group were transfusion-dependent. Most patients
had received some form of treatment before transplan-
tation (ie, ATG, CsA, androgens, steroids, G-CSF, or
combinations thereof). The interval from diagnosis to
transplantation ranged from 1 month to 36 years (me-
dian, 21months). It was significantly longer after unre-
lated transplantation than after related transplantation
(11 months to 28 years [median, 14 years] vs 1 month
to 36 years [median, 11 months]; P 5 .0003, Mann-
WhitneyU test). The 2 patients who underwent trans-
plantation 28 and 36 years after diagnosis were
observed without therapy in childhood. They received
immunosuppressive therapy because of progressive
pancytopenia 20 years after diagnosis, but it was not ef-
fective. They decided to undergo allo-SCT after be-
coming transfusion-dependent. Thirty-three patients
received HLA-matched related transplants (30 from
siblings, 2 from fathers, and 1 from a son). Sixteen
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HLA-matched transplants and 6 HLA-mismatched
(2 HLA-A allele mismatch, 2 HLA-DRB1 allele mis-
match, and 2 HLA-DR serologic mismatch) trans-
plants. Twenty-eight patients were conditioned with
Cy 1 TLI for related transplants, and 14 were condi-
tioned with Cy 1 TBI 1 TLI for unrelated trans-
plants. Five patients with high risk for graft failure
who received related transplants were conditioned
with the same regimen used for unrelated transplants;
1 of these patients had received heavy transfusions, 1
patient had a high titer of anti-D antibody, and 3 pa-
tients had received a transplant from a father or
a son. Two patients who received unrelated transplants
were conditioned with Cy (200 mg/kg) 1 TLI (750
cGy) 1 ATG (10 mg/kg).
Engraftment
Graft failure developed in 2 of the 49 patients
(4.1%). One patient who experienced primary graft
Table 1. Patient characteristics
Number of patients 49
Median age, years (range) 24 (16 to 47)
Etiology of aplastic anemia
Idiopathic 47
Hepatitis 2
Severity
Moderate 8
Severe 41
Previous treatment
None 2
Corticosteroid 29
ATG 16
CsA 21
Anabolic steroid 22
G-CSF, erythropoietin 10
Median units of previous transfusions
Red blood cell 44
Platelet 90
Donor and HLA matching
Related match 33
Unrelated match 10
Unrelated mismatch 6
Median BM cells harvested, 108/kg (range) 3.2 (1.8 to 6.9)
Conditioning regimen for related
transplantation
Cy 1 TLI 7.5Gy 28
Cy 1 TBI 5Gy 1 TLI 5Gy 5
Conditioning regimen for unrelated
transplantation
Cy 1 TBI 5Gy 1 TLI 5Gy 10
Cy 1 TBI 5Gy 1 TLI 5Gy 1 ATG 4
Cy 1 TLI 7.5Gy 1 ATG 2
GVHD prophylaxis
CsA 1 MTX 37
Tacrolimus 1 MTX 10
CsA 2
ABO compatibility
Match 31
Major mismatch 5
Minor mismatch 9
Major-minor mismatch 4failure after receiving an HLA-matched unrelated
transplant with conditioning with Cy 1 TLI 1 ATG
received a second CD34-purified transplantation
from his haploidentical brother and achieved
sustained engraftment, but subsequently died of CMV
infection and heart failure 37 days after the second
transplantation. Another patient experienced late graft
failure 161 days after receiving an HLA-matched re-
lated transplant with conditioning with Cy 1 TLI.
He received a second transplant from the same donor
and achieved sustained engraftment, but died of idio-
pathic interstitial pneumonia 64 days after the second
transplantation. Sustained engraftment was achieved
in all of the other evaluable patients.
OS, Relapse, Mortality, and Cause of Death
Currently, 41 patients are alive with a median fol-
low-up of 7 years (range, 7 months to 23 years). The
estimated overall 7-year OS was 81% (Figure 1). It
was not statistically significantly different between
those receiving related transplants and those receiving
unrelated transplants (82%vs 81%;P5 .65) (Figure 2).
None of the patients experienced recurrence of AA.
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Figure 1. OS was 81% at 7 years.
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Figure 2.OS was not significantly different between related and un-
related transplantation (82% vs. 81%; P 5 .65).
46 Y. Inamoto et al.Table 2. Relative risk of death after transplantation
Univariate analysis Multivariate analysis
Variable Adverse factor Hazard ratio (95% CI) P Hazard ratio (95% CI) P
Previous ATG treatment Yes 17 (2.1 to 140) .008 15 (1.8 to 120) .012
Previous RBC transfusion . 45 units 1.8 (0.47 to 8.3) .42
Previous platelet transfusion . 90 units 2.0 (0.47 to 8.3) .36
Diagnosis to transplantation . 2 years 4.0 (0.80 to 20) .092 2.8 (0.55 to 14) .22
Patient age . 40 years 1.9 (0.23 to 15) .55
Donor Unrelated 1.4 (0.33 to 5.8) .65
HLA compatibility Mismatch 1.2 (0.14 to 9.6) .88
Sex mismatch Female to male 2.6 (0.65 to 10) .65
ABO compatibility Mismatch 3.1 (0.74 to 13) .12
ATG use in conditioning Yes 2.8 (0.56 to 14) .21
GVHD prophylaxis CsA ± MTX UE* .19*
UE indicates unevaluable.
*All 10 patients with the GVHD prophylaxis of tacrolimus 1 methotrexate are alive (P 5 .19; log- rank test).In univariate analyses, a history of previous treat-
ment with ATG was the sole significant factor associ-
ated with lower survival rates (relative risk [RR] 5 17;
95% confidence interval [CI] 5 2.1-140). There was
a trend toward lower survival rates in patients with
more than 2 years from diagnosis to transplantation
(RR5 4.0; 95%CI5 0.80-20). None of the other fac-
tors listed in Table 2 were prognostic. In multivariate
analyses, a history of previous treatment with ATG re-
mained a significant factor, and the interval from diag-
nosis to transplantation was not prognostic.
Four patients (8%) died within 100 days after
transplantation, from brain hemorrhage, GM-CSF–
induced acute respiratory distress syndrome, primary
graft failure, and pneumonia after BLPD. Four others
(8%) died more than 100 days after transplantation,
from different causes, including late graft failure, hy-
poglycemia, Staphylococcus pneumoniae sepsis, and Pseu-
domonas aeruginosa sepsis during immunosuppressive
treatment for scleroderma. The latter 2 patients had
extensive cGVHD. The patient who died of hypogly-
cemia received insulin injections for diabetes resulting
from transfusion-induced hemochromatosis.
GVHD
Grade II-IV aGVHD developed in 11 patients, for
a cumulative incidence of 23% (Figure 3A). This inci-
dence was not statistically significant between related
and unrelated transplant recipients (18% vs 31%;
P 5 .26). Grade III aGVHD developed in only 1 pa-
tient after related transplantation, and no patients
developed grade IV aGVHD.
Chronic GVHD developed in 14 of 44 evaluable
patients, for a cumulative incidence of 29% (Fig-
ure 3B); the difference in incidence between related
and unrelated transplant recipients was not statistically
significant (28% vs 32%; P 5 .68). Of the 14 patients
with cGVHD, 1 had the limited type and 13 had theextensive type, whereas 5 had previous aGVHD.
Female-to-male transplantation was the sole signifi-
cant factor associated with cGVHD (RR 5 3.1; 95%
CI 5 1.1-8.9) (Table 3).
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Figure 3. Cumulative incidence of GVHD: (A) grade II-IV aGVHD,
23%; (B) cGVHD, 29%.
TLI Conditioning for Aplastic Anemia 47Table 3. Relative risk of chronic GVHD after transplantation in the 44 evaluable patients
Univariate analysis
Variable Risk factor Hazard ratio (95% CI) P
Previous ATG treatment Yes 1.1 (0.35 to 3.6) .85
Previous RBC transfusion .45 units 0.57 (0.19 to 1.7) .31
Previous platelet transfusion .90 units 1.5 (0.53 to 4.4) .78
Diagnosis to transplantation . 2 years 0.96 (0.33 to 2.8) .93
Patient age . 40 years 0.81 (0.11 to 6.3) .84
Donor Unrelated 1.5 (0.51 to 4.5) .46
HLA compatibility Mismatch UE* .14*
Sex mismatch Female to male 3.1 (1.1 to 8.9) .034
ABO compatibility Mismatch 0.97 (0.32 to 2.9) .95
Previous acute GVHD Yes 1.7 (0.58 to 5.1) .33
ATG use in conditioning Yes 0.82 (0.11 to 6.3) .85
UE indicates unevaluable.
*Chronic GVHD did not develop in any of the 6 evaluable patients after HLA-mismatched transplantation (P 5 .14; log-rank test).Other Transplantation-Related Complications
Fifteen patients (31%) experienced a total of 16 ep-
isodes of other transplantation-related complications,
including BLPD (n 5 3), Cy-induced hemorrhagic
cystitis (n 5 2), adenovirus-induced hemorrhagic cys-
titis (n5 1), capillary leak syndrome (n5 1), radiation
pneumonia (n 5 1), radiation hepatitis (n 5 1), osteo-
necrosis (n 5 1), pericardial effusion (n 5 1), pure red
cell aplasia (n 5 1), bronchiolitis obliterance organiz-
ing pneumonia (BOOP; n5 1), syndrome of inappro-
priate antidiuretic hormone secretion (n 5 1),
idiopathic thrombocytopenic purpura (ITP; n 5 1),
and engraftment syndrome (n 5 1). All but 3 patients
(those with BLPD, osteonecrosis, and ITP) recovered
from their complications. No secondary malignancies
other than BLPD developed in any patient.
DISCUSSION
Conditioning with Cy alone was the initial regi-
men used for AA, but this has been associated with
a high incidence of graft rejection (9%-19%) [8,18],
particularly in patients receiving transfusions. The ad-
dition of TLI was used to reduce graft rejection, and
favorable results were reported in small numbers of pa-
tients [13,14,19,20]. Novitzky et al. [21] reported that
radiation-containing conditioning led to universal en-
graftment despite T cell depletion. The present study
demonstrated satisfactory results and long-term effi-
cacy in a larger number of transfused patients. More-
over, a further addition of low-dose (5 Gy) TBI was
feasible and effective for engraftment after unrelated
transplantation, whereas the incidence of graft
rejection was reportedly higher for this population
[22-24]. Although ATG is widely used for unrelated
transplantation [25,26], our results show that it likely
is not useful for engraftment if radiation-containing
conditioning is used. A recently randomized study
conducted by the International Bone Marrow Trans-plant Registry failed to show the advantage of
ATG 1 Cy over Cy alone [27]. Of note, the rate of
graft failure was as high as 16%-18%, significantly
higher than that found in our study (P 5 .026).
Although novel conditioning regimens without irra-
diation, including fludarabine or Campath-1H, are
being investigated for AA [28-30], their impact on in-
fectious complications, GVHD, and long-term out-
comes is not yet well known. ATG may be useful in
association with these regimens without irradiation.
Furthermore, results may vary depending on the type
and dose of ATG used.
In the current study, our results after unrelated
transplantation were comparable to those after related
transplantation, despite the longer interval from diag-
nosis to transplantation. Survival rates after unrelated
transplantation were reported to range from 20% to
61% [22-24,31,32], and Kojima et al. [33] concluded
that ATG as part of the conditioning regimen im-
proved survival rates. However, the use of ATG in
conditioning regimens was not associated with OS in
the current study. Our survival rate of 81% was satis-
factory even though most of our patients did not re-
ceive ATG, and it is noteworthy that BLPD
developed only after ATG conditioning. Therefore,
we conclude that ATG is not necessary in conditioning
for AA if radiation-containing conditioning is used.
Another recent report also failed to show any advan-
tage of ATG on outcome [27].
Many studies have identified the interval from di-
agnosis to transplantation as a risk factor for survival
[8,33,34]. However, this interval was not found to be
a significant factor affecting OS in the current study.
Even when transplantation was performed after 2
years from diagnosis, the OS rate at 7 years was
70%. TLI conditioning is promising for adult patients
with AA. A history of previous treatment with ATG
may decrease OS when combined with TLI condi-
tioning. Interestingly, all 10 patients who received
48 Y. Inamoto et al.tacrolimus and MTX as GVHD prophylaxis are alive.
Although these patients constitute a relatively small
group, the efficacy of tacrolimus is a promising subject
for future investigation.
The TLI conditioning was well tolerated in the
current study. Two patients developed irradiation-
related pneumonia and hepatitis, but they recovered
with no medication therapy. Deeg et al. [32] recently
reported that the optimal dose of TBI for unrelated
bone marrow transplantation was 200 cGy and that
a higher dose could increase pulmonary toxicity. How-
ever, such toxicity was not common in the present
study. We believe that radiation dose and dosimetry
are almost optimal if radiation is given in fractions. Re-
ducing the radiation dose to the lungs is an important
and interesting issue, but in the present study, the cu-
mulative lung dose was about 6Gy evenwith the TBI1
TLI regimen. A dose of 6 Gy is lower than the safe
dose of 9 Gy recently reported by Soule et al. [35].
Thus, reducing the radiation dose may not be neces-
sary, considering the increased risk of graft rejection.
Our mortality rate of 8% on day 100 was relatively
high, but any association between the irradiation con-
ditioning and cause of death was unlikely. Most of the
early deaths were related to patients’ background fac-
tors, including ATG as part of the conditioning and
GM-CSF. Although cataracts and endocrine dysfunc-
tion have been reported after TBI conditioning [36],
these complications were not found in the current
study. Of note, 2 patients with extensive cGVHD
died from sepsis (Staphylococcus and Pseudomonas)
more than 3 years after transplantation. Therefore,
the long-term prevention of infection is of great im-
portance to reduce long-term mortality, particularly
in patients with cGVHD.
Although the use of irradiation as part of the con-
ditioning regimen has been reported to increase
aGVHD (35%-53%) [8,34], the incidence of aGVHD
was as low as 23% in the present study. TLI may play
a role in protecting against aGVHD; recent investiga-
tions have found that the increased percentage of host
natural killer (NK) T cells after TLI could reduce
aGVHD [37]. Tissue damage after a conditioning reg-
imen is hypothesized to increase aGVHD. TLI is less
likely to cause tissue damage. cGVHD is considered
a main cause of death after long-term follow-up of
allo-SCT among patients with AA [2]. In the current
study, the incidence of cGVHD was as low as 29%,
lower than the 60% reported in previous studies
[34,38]. Because univariate analyses showed that
female-to-male transplantation was the sole factor
affecting cGVHD, sex matching as well as HLA
matching is important.
Several studies have reported an increased risk of
secondary malignancies after irradiation conditioning
[3,34,38,39]. In the current study, however, malig-
nancies other than BLPD failed to develop afterlong-term follow-up. One reason for this is the lim-
ited field of irradiation; another is the low incidence
of cGVHD. Interestingly, an Italian group reported
no secondary malignancies after Cy 1 TLI condi-
tioning, and their incidence of cGVHD was as low
as 35% [19]. Our data demonstrate that limited field
irradiation does not induce secondary malignancies.
In summary, our findings indicate that TLI condi-
tioning is feasible and effective for adult patients
with AA.
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